Abstract Library

#2162 Single Cell Copy Number Variation Analysis (CNV) of Circulating Tumor Cells (CTCs) in Neuroendocrine Tumor (NET) Patients

Introduction: The identification and characterization of CTCs as part of a minimally invasive “liquid biopsy” provides an opportunity to explore NET biology, identify therapeutic targets and investigate tumour heterogeneity.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Childs A

Authors: Childs A, Vesely C, Rizzo F, Ensell L, Lowe H,

Keywords: CTCs, tumor heterogeneity, CNV,

#1364 Clinical Utility of EpCAM-positive Circulating Tumor Cells in Neuroendocrine Neoplasms Using the CellSearch Platform

Introduction: Circulating tumor cells are captured to predict the prognosis of patients in many types of cancers, but reports are rare on clinical utility and tumor cell shedding in neuroendocrine neoplasms (NENs).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Xin B, Han X, Zhou J, Xu X, Ji Y,

Keywords: nen, ctc, cell search,

#922 Comparison of the Novel Cell Detector Method with Cell Search Technology in the Isolation of Circulating Tumor Cells in Neuroendocrine Tumors

Introduction: Circulating Tumor Cells (CTCs) have been detected in patients with neuroendocrine tumors (NET) using the CellSearch platform. Their presence is associated with a worse clinical outcome but less than 50% patients have detectable cells. The GILUPI Cell Detector is an EpCAM coated wire that is inserted into a vein and has been developed to increase capture of CTCs.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Mandair D, Ensell L, Vesely C, Lowe H, Caplin M,

Keywords: CTCs, EpCAM, neuroendocrine,

#88 EpCam expression and detection of circulating tumor cells in neuroendocrine tumors

Introduction: Using the CellSearchTM system, circulating tumor cells (CTCs) can be reproducibly enumerated according to expression of EpCAM and cytokeratins 8, 18 or 19 and the absence of the haemopoietic marker CD45. The number of CTCs detected in 7.5 mls blood has been shown to correlate with prognosis in breast, colon and prostate cancer and can predict response to therapy. Neuroendocrine tumors (NETs) have not previously been reported to express EpCAM and have not been systematically assessed for presence of CTCs. We have therefore explored the expression of EpCAM in NETs and the detection of NET cells in the circulation.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Khan M

Authors: Khan M, Tsigani T, Rashid M, Luong T, Caplin M,

Keywords: neuroendocrine tumor, circulating tumor cells, carcinoid, EpCAM,